This paper provides the first quantitative economic models of pharmacy benefit management regulation. The price-theoretic models allow for various market frictions and imperfections including market power, coordination costs, tax distortions, and incomplete innovation incentives. A rigorous economic interpretation is provided for what are sometimes called “rebate walls” or “rebate traps.” Applicable types of regulation include rebate rules, such as the HHS rebate rule and the Insulin Act; disclosure requirements such as the PBM Transparency Act of 2023; and pharmacy contract restrictions such as the CMS Medicare rule to take effect in 2024. Utilization of brands and generics, plan spending, cost sharing, spillovers to nonpharmacy medical spending, government budgets, and the pace of drug innovation are among the outcomes tracked by the open-source model.

More on this topic

BFI Working Paper·Oct 21, 2026

The Impact of the Great Recession on Mortality: A Dynamic Factor Analysis

Amy Finkelstein, Matthew Notowidigdo, and Enzo Profili
Topics: Health care
BFI Working Paper·Oct 12, 2026

Gains from Trade in Gun Policy: A Compensation-Based Benchmark

Brad Shapiro, Sara Drango, and Sarah Moshary
Topics: Fiscal Studies, Health care
BFI Working Paper·Oct 6, 2026

Provider and Worker Responses to Supply-Side Audits in Social Insurance

Pablo A. Celhay, Nicolás Figueroa, Carla Guadalupi, and Benjamín Oteíza
Topics: Health care